ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-positive advanced or metastatic gastric or gastroesophageal cancer: a meta-analysis of single-arm trials.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrastuzumab deruxtecan (T-DXd) has demonstrated clinical activity in HER2-positive advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following trastuzumab failure. However, variability across studies has limited a comprehensive assessment of its efficacy and safety.
methodsA systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed, Scopus, and Cochrane databases were searched through September 2025. Prospective studies evaluating T-DXd in HER2-positive gastric or GEJ adenocarcinoma were included. Outcomes were pooled using a random-effects model and reported as proportions with 95% confidence intervals (CIs).
resultsEight trials (range of median follow-up 8.3-16.8 months) comprising 1,182 patients were included, with 77.9% treated in the second-line or later setting. The pooled objective response rate (ORR) was 42.7% (95% CI 36.9-48.6; I
conclusionsT-DXd demonstrates meaningful antitumor activity and survival benefit in HER2-positive gastric and GEJ adenocarcinoma, with a clinically relevant toxicity profile requiring careful monitoring.
Indexed as
Identifiers
42240809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.